Kaisi Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd.

Primary study objective: To evaluate the pharmacokinetic characteristics of CS0159 in healthy subjects with mild hepatic impairment (Child-Pugh: Class A), moderate hepatic impairment (Child-Pugh: Class B) and normal hepatic function matched by gender, age and weight, and to provide a scientific basis for the rational clinical use of drugs in subjects with hepatic impairment. Secondary study objective: To evaluate the safety of CS0159 in healthy subjects with mild hepatic impairment (Child-Pugh: Class A), moderate hepatic impairment (Child-Pugh: Class B) and normal hepatic function. Exploratory objective: To evaluate the correlation between baseline liver function indicators and PK parameters of CS0159.